Image

Technology Assisted Nudging to Increase Physical Activity Among Hospitalised Medical Patients

Recruiting
60 years of age
Both
Phase N/A

Powered by AI

Overview

Primary Objective To investigate if patients hospitalised for older adults with a decreased level of physical function, either related to a chronic condition e.g., COPD, Congestive heart failure, renal failure; infections; frailty and tendency of falling; orthopaedic surgery - after hip fracture will increase their time spent out of bed during hospitalisation and 3 months after discharge through visual feedback and motivational intervention about physical activities from a new mobile technology.

Hypothesis Patients hospitalised for medical disease will increase their physical activity level during hospitalisation and 3 months after discharge through visual feedback and motivational intervention from a new mobile technology.

Description

STUDY DESIGN Description of the protocol The study will be conducted as a randomised multicentre trial including 3 hospitals in Europe (Copenhagen, Stavanger, and Genova). Patients admitted to Department of Respiratory Medicine, Department of Cardiology, and Department of Geriatrics, Department of Orthopaedic disease or Department of Neurology will be included, and they will have their physical activity level measured either with or without a monitor providing visual feedback of time spent bedridden, sitting, standing, and walking. After discharge the feedback will include an ergometer bike or sofa bike connected to the feedback mechanism.

Design A randomised multicentre study design is chosen. All participants will have their physical activity measured during hospitalisation and after discharge. Approximately half of the participants will receive visual feedback about the amount of physical activity from a mobile device placed on the bedside table while hospitalized, and after discharge, they will be provided with an ergometer bike or sofa bike connected to the feedback mechanism.

Allocation of participants The allocation of participants will be done 1 to 1, stratified by age group, gender, and level of mobility, to the control group (no feedback) and intervention group (visual feedback group). We schedule, that 162 patients will be possible to include in the analysis set (54 patients are planned to be included in Denmark, Norway, and Italy). A computer-generated randomisation sequence will be used to assign the participants in each site to the intervention and control arms.

Duration of study participation Each participant will be observed from admission of hospitalisation or until he/she is discharged and followed for 3 months.

Eligibility

Inclusion Criteria:

        An individual will be eligible for study participation if he/she meets the following
        criteria:
        Aged ≥60
          1. Is admitted to one of the participating departments
          2. Has signed informed consent
          3. Reads and speaks Danish, Norwegian, Italian, or English
        Exclusion Criteria:
        An individual will be excluded from the study if he/she meets any of the following
        criteria:
          1. Any condition that, in the opinion of the investigator, makes the person unfit for
             participation, e.g., delirium and/or psychotic symptoms; moderate or severe depression
             (GDS>8 (short form)); major surgery; moderate/severe dementia (MoCA≤18); chemotherapy
             or radiation treatment ongoing at enrolment; moderate/severe frailty (CFS≥6)
          2. Expected hospitalisation less than 24 hours
          3. Has allergy towards band aid
          4. Enrolled in any other clinical study within the duration of the current study.
        While these criteria represent the criteria for being observed, only patients observed for
        at least 24 hours are included in the analysis population. For practical reasons it is not
        possible to predict those patients eligible for the analysis population at inclusion.
        Hence, we will monitor more patients than we will analyse (see statistical analysis
        section).

Study details

COPD, Heart Failure, Parkinson Disease, Arthritis, Old Age; Cachexia

NCT06336252

Bispebjerg Hospital

16 April 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.